Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

oHSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.

Yoo JY, Swanner J, Otani Y, Nair M, Park F, Banasavadi-Siddegowda Y, Liu J, Jaime-Ramirez AC, Hong B, Geng F, Guo D, Bystry D, Pelphs M, Quadri H, Lee TJ, Kaur B.

Neuro Oncol. 2019 May 7. pii: noz079. doi: 10.1093/neuonc/noz079. [Epub ahead of print]

PMID:
31063549
2.

Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966.

Lee TJ, Nair M, Banasavadi-Siddegowda Y, Liu J, Nallanagulagari T, Jaime-Ramirez AC, Guo JY, Quadri H, Zhang J, Bockhorst KH, Aghi MK, Carbonell WS, Kaur B, Yoo JY.

Mol Cancer Ther. 2019 Jun;18(6):1127-1136. doi: 10.1158/1535-7163.MCT-18-0953. Epub 2019 Mar 29.

PMID:
30926634
3.

PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance.

Russell L, Swanner J, Jaime-Ramirez AC, Wang Y, Sprague A, Banasavadi-Siddegowda Y, Yoo JY, Sizemore GM, Kladney R, Zhang J, Lehman NL, Ostrowski MC, Hong B, Caligiuri M, Yu J, Kaur B.

Nat Commun. 2018 Nov 27;9(1):5006. doi: 10.1038/s41467-018-07344-1.

4.

Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.

Jaime-Ramirez AC, Yu JG, Caserta E, Yoo JY, Zhang J, Lee TJ, Hofmeister C, Lee JH, Kumar B, Pan Q, Kumar P, Baiocchi R, Teknos T, Pichiorri F, Kaur B, Old M.

Mol Ther Oncolytics. 2017 May 10;5:87-96. doi: 10.1016/j.omto.2017.05.002. eCollection 2017 Jun 16.

5.

Activation of the FcgammaReceptorIIIa on human natural killer cells leads to increased expression of functional interleukin-21 receptor.

McMichael EL, Courtney NB, Duggan MC, Wesolowski R, Quiroga D, Kondadasula SV, Atwal LS, Bhave N, Luedke E, Jaime-Ramirez AC, Campbell AR, Mo X, Byrd JC, Carson Iii WE.

Oncoimmunology. 2017 May 2;6(5):e1312045. doi: 10.1080/2162402X.2017.1312045. eCollection 2017.

6.

RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21.

Lee TJ, Yoo JY, Shu D, Li H, Zhang J, Yu JG, Jaime-Ramirez AC, Acunzo M, Romano G, Cui R, Sun HL, Luo Z, Old M, Kaur B, Guo P, Croce CM.

Mol Ther. 2017 Jul 5;25(7):1544-1555. doi: 10.1016/j.ymthe.2016.11.016. Epub 2017 Jan 18.

7.

Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.

Jaime-Ramirez AC, Dmitrieva N, Yoo JY, Banasavadi-Siddegowda Y, Zhang J, Relation T, Bolyard C, Wojton J, Kaur B.

J Gene Med. 2017 Mar;19(3). doi: 10.1002/jgm.2942.

8.

Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.

Yoo JY, Jaime-Ramirez AC, Bolyard C, Dai H, Nallanagulagari T, Wojton J, Hurwitz BS, Relation T, Lee TJ, Lotze MT, Yu JG, Zhang J, Croce CM, Yu J, Caligiuri MA, Old M, Kaur B.

Clin Cancer Res. 2016 Nov 1;22(21):5265-5276. Epub 2016 Jul 7. Erratum in: Clin Cancer Res. 2017 Mar 1;23 (5):1359-1360.

9.

The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.

Suarez-Kelly LP, Kemper GM, Duggan MC, Stiff A, Noel TC, Markowitz J, Luedke EA, Yildiz VO, Yu L, Jaime-Ramirez AC, Karpa V, Zhang X, Carson WE 3rd.

Oncotarget. 2016 Dec 6;7(49):81172-81186. doi: 10.18632/oncotarget.12791.

10.

IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells.

McMichael EL, Jaime-Ramirez AC, Guenterberg KD, Luedke E, Atwal LS, Campbell AR, Hu Z, Tatum AS, Kondadasula SV, Mo X, Tridandapani S, Bloomston M, Ellison EC, Williams TM, Bekaii-Saab T, Carson WE 3rd.

Clin Cancer Res. 2017 Jan 15;23(2):489-502. doi: 10.1158/1078-0432.CCR-16-0004. Epub 2016 Jul 19.

11.

Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions.

Skinner CC, McMichael EL, Jaime-Ramirez AC, Abrams ZB, Lee RJ, Carson WE 3rd.

Melanoma Res. 2016 Aug;26(4):329-37. doi: 10.1097/CMR.0000000000000258.

12.

NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.

Jaime-Ramirez AC, McMichael E, Kondadasula S, Skinner CC, Mundy-Bosse BL, Luedke E, Jones NB, Mani A, Roda J, Karpa V, Li H, Li J, Elavazhagan S, La Perle KM, Schmitt AC, Lu Y, Zhang X, Pan X, Mao H, Davis M, Jarjoura D, Butchar JP, Poi M, Phelps M, Tridandapani S, Byrd JC, Caligiuri MA, Lee RJ, Carson WE 3rd.

Cancer Immunol Res. 2016 Apr;4(4):323-336. doi: 10.1158/2326-6066.CIR-15-0168. Epub 2016 Feb 10.

13.

Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.

Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM, Byrd JC, Baiocchi R, Kaur B, Hofmeister CC, Pichiorri F.

Mol Cancer Ther. 2016 May;15(5):830-41. doi: 10.1158/1535-7163.MCT-15-0240-T. Epub 2016 Jan 25.

14.

The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.

Martin del Campo SE, Levine KM, Mundy-Bosse BL, Grignol VP, Fairchild ET, Campbell AR, Trikha P, Mace TA, Paul BK, Jaime-Ramirez AC, Markowitz J, Kondadasula SV, Guenterberg KD, McClory S, Karpa VI, Pan X, Olencki TE, Monk JP, Mortazavi A, Tridandapani S, Lesinski GB, Byrd JC, Caligiuri MA, Shah MH, Carson WE 3rd.

J Immunol. 2015 Sep 1;195(5):1995-2005. doi: 10.4049/jimmunol.1400084. Epub 2015 Aug 3.

15.

The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.

Meisen WH, Wohleb ES, Jaime-Ramirez AC, Bolyard C, Yoo JY, Russell L, Hardcastle J, Dubin S, Muili K, Yu J, Caligiuri M, Godbout J, Kaur B.

Clin Cancer Res. 2015 Jul 15;21(14):3274-85. doi: 10.1158/1078-0432.CCR-14-3118. Epub 2015 Mar 31.

16.

MiR-21 enhances melanoma invasiveness via inhibition of tissue inhibitor of metalloproteinases 3 expression: in vivo effects of MiR-21 inhibitor.

Martin del Campo SE, Latchana N, Levine KM, Grignol VP, Fairchild ET, Jaime-Ramirez AC, Dao TV, Karpa VI, Carson M, Ganju A, Chan AN, Carson WE 3rd.

PLoS One. 2015 Jan 14;10(1):e0115919. doi: 10.1371/journal.pone.0115919. eCollection 2015.

17.

Changes in BAI1 and nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targeted therapies.

Meisen WH, Dubin S, Sizemore ST, Mathsyaraja H, Thies K, Lehman NL, Boyer P, Jaime-Ramirez AC, Elder JB, Powell K, Chakravarti A, Ostrowski MC, Kaur B.

Mol Cancer Ther. 2015 Jan;14(1):307-14. doi: 10.1158/1535-7163.MCT-14-0659. Epub 2014 Nov 5.

18.

Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.

Luedke E, Jaime-Ramirez AC, Bhave N, Roda J, Choudhary MM, Kumar B, Teknos TN, Carson WE 3rd.

Surgery. 2012 Sep;152(3):431-40. doi: 10.1016/j.surg.2012.05.035. Epub 2012 Jul 6.

19.

Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.

Luedke E, Jaime-Ramirez AC, Bhave N, Carson WE 3rd.

J Immunother. 2012 Jun;35(5):367-73. doi: 10.1097/CJI.0b013e3182562d76. Review.

20.

Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.

Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, Kuppusamy P, Guenterberg K, Kondadasula SV, Chaudhury AR, La Perle KM, Kreiner M, Young G, Guttridge DC, Carson WE 3rd.

Cancer Res. 2011 Aug 1;71(15):5101-10. doi: 10.1158/0008-5472.CAN-10-2670. Epub 2011 Jun 16.

21.

Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4⁺ and CD8⁺ T cells.

Guenterberg KD, Lesinski GB, Mundy-Bosse BL, Karpa VI, Jaime-Ramirez AC, Wei L, Carson WE 3rd.

Cancer Immunol Immunother. 2011 Sep;60(9):1281-8. doi: 10.1007/s00262-011-1034-2. Epub 2011 May 21.

22.

IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production.

Jaime-Ramirez AC, Mundy-Bosse BL, Kondadasula S, Jones NB, Roda JM, Mani A, Parihar R, Karpa V, Papenfuss TL, LaPerle KM, Biller E, Lehman A, Chaudhury AR, Jarjoura D, Burry RW, Carson WE 3rd.

J Immunol. 2011 Mar 15;186(6):3401-9. doi: 10.4049/jimmunol.1000328. Epub 2011 Feb 14.

Supplemental Content

Loading ...
Support Center